comparemela.com

Latest Breaking News On - Matter patent - Page 2 : comparemela.com

Investegate |F-star Therapeutics, Inc Announcements | F-star Therapeutics, Inc : F-star Granted Composition of Matter Patent for FS118, a Bispecific Antibody Targeting LAG-3 and PD-L1

F-star Granted Composition of Matter Patent for FS118, a Bispecific Antibody Targeting LAG-3 and PD-L1 Patent protects Company’s lead clinical asset FS118 throughout Europe CAMBRIDGE, United Kingdom and CAMBRIDGE, Mass., Jan. 20, 2021 (GLOBE NEWSWIRE) F-star Therapeutics, Inc. (NASDAQ: FSTX), a clinical-stage biopharmaceutical company dedicated to developing next generation immunotherapies to transform the lives of patients with cancer, today announces the European Patent Office (EPO) has granted a patent with claims protecting the composition of matter of F-star’s FS118 molecule throughout Europe. The expiry date of the patent, not including any potential extensions to the standard 20-year term of protection, is expected to be June 2037.

© 2024 Vimarsana

vimarsana © 2020. All Rights Reserved.